Sitagliptin
Sitagliptin is a once-daily DPP-4 inhibitor used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 20 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Sitagliptin (Januvia) is a common add-on to metformin for type 2 diabetes (not type 1), blocking the DPP-4 enzyme so gut hormones prompt more insulin and less glucagon, a sugar-raising hormone; on the market since about 2006, it is available as a generic. It is among the gentlest diabetes medicines, rarely causing low blood sugar or weight gain on its own, and side effects are usually mild, like a stuffy nose, sore throat or headache. Stop it and get help for severe stomach pain spreading to your back (possible pancreatitis, an inflamed pancreas) or a swollen face or throat, and report breathlessness or sudden weight gain (possible heart failure).
Clinical pearls
- Your kidneys clear sitagliptin, so expect kidney blood tests before starting and periodically after, because weaker kidneys need a lower dose.
- With insulin or a sulfonylurea like glipizide, low blood sugar becomes possible, so that other medicine's dose may be lowered.
- Measure Brynovin oral solution with a marked oral syringe or dosing cup in mL, never a kitchen spoon.
- Tell your doctor about severe joint pain or skin blisters, two lesser-known sitagliptin side effects that can mean stopping it.
Patient information guide A plain-language walkthrough of Sitagliptin, written from its FDA label.
What Sitagliptin is used for
▾
Sitagliptin is used to help control blood sugar in adults with type 2 diabetes.
- Sitagliptin tablets, Januvia, Zituvio and Brynovin oral solution are each used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- It should not be used in type 1 diabetes.
- It has not been studied in people with a history of pancreatitis.
How Sitagliptin works
▾
Sitagliptin blocks an enzyme called DPP-4. This enzyme normally breaks down incretin hormones (GLP-1 and GIP) that your gut releases after meals.
With more of these hormones active for longer, your body releases more insulin and makes less glucagon when blood sugar is normal or high. Blood sugar then comes down.
Sitagliptin dosage
▾
Sitagliptin is taken by mouth once a day, with or without food. It comes as tablets (including Januvia and Zituvio) and as Brynovin oral solution.
- Brynovin should be measured with an oral syringe or dosing cup marked in mL.
- People with reduced kidney function need a lower dose, so kidney function is checked before starting and periodically afterward.
- Tablets can be taken without regard to the timing of dialysis.
Follow your prescriber's directions and your pharmacy label.
Dosing details from the FDA-approved label
From the Sitagliptin prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Recommended dosage (general; eGFR greater than or equal to 45 mL/min/1.73 m2 to less than 90 mL/min/1.73 m2)
- 100 mg orally once daily (oral solution: 100 mg (4 mL) once daily)
- Can be taken with or without food
- No dosage adjustment required for eGFR greater than or equal to 45 mL/min/1.73 m2 to less than 90 mL/min/1.73 m2
- Moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73 m2 to less than 45 mL/min/1.73 m2)
- 50 mg once daily (oral solution: 50 mg (2 mL) once daily)
- Assess renal function prior to initiation and periodically thereafter
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis
- 25 mg once daily (oral solution: 25 mg (1 mL) once daily)
- May be administered without regard to the timing of dialysis
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION The recommended dose of sitagliptin tablets is 100 mg once daily. Sitagliptin tablets can be taken with or without food. ( 2.1 ) Dosage adjustment is recommended for patients with eGFR less than 45 mL/min/1.73 m 2 . ( 2.2 ) Dosage Adjustment in Patients with Renal Impairment ( 2.2 ) eGFR greater than or equal to 30 mL/min/1.73 m 2 to less than 45 mL/min/1.73 m 2 eGFR less than 30 mL/min/1.73 m 2 (including patients with end stage renal disease [ESRD] on dialysis) 50 mg once daily 25 mg once daily 2.1 Recommended Dosing The recommended dose of sitagliptin tablets is 100 mg once daily. Sitagliptin tablets can be taken with or without food. 2.2 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of sitagliptin tablets and periodically thereafter. For patients with an estimated glomerular filtration rate [eGFR] greater than or equal to 45 mL/min/1.73 m 2 to less than 90 mL/min/1.73 m 2 , no dosage adjustment for sitagliptin tablets is required. For patients with moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73 m 2 to less than 45 mL/min/1.73 m 2 ), the dose of sitagliptin tablets is 50 mg once daily. For patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m 2 ) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of sitagliptin tablets is 25 mg once daily. Sitagliptin may be administered without regard to the timing of dialysis.
Read the full Dosage and Administration section on DailyMed →
Sitagliptin side effects
▾
Most people tolerate sitagliptin well. Commonly reported effects include:
Common side effects
- Stuffy or runny nose and sore throat (nasopharyngitis)
- Upper respiratory tract infection
- Headache
- Low blood sugar (hypoglycemia) when used with insulin or a sulfonylurea
- Swelling in the legs or hands (peripheral edema) was reported in one longer study
- Nausea, diarrhea or abdominal pain, reported in a small number of people
- Low blood sugar when combined with insulin or a sulfonylurea
When to get medical help
- Severe stomach pain that may spread to your back, with or without vomiting. These can be signs of pancreatitis. Stop the medicine and call your doctor right away.
- Swelling of the face, lips, tongue or throat, trouble breathing, or a severe rash or peeling skin. These can be serious allergic reactions. Stop the medicine and get help right away.
- Shortness of breath, sudden weight gain or swelling. These can be signs of heart failure, so report them right away.
- Little urine, or sudden worsening of kidney function. Acute kidney failure has been reported, sometimes needing dialysis.
- Severe or disabling joint pain. Tell your doctor, who may stop the medicine.
- Blisters or skin erosions. These can be bullous pemphigoid (a blistering skin condition) and need prompt medical review.
- Shakiness, sweating, confusion or fast heartbeat from low blood sugar, especially if you also use insulin or a sulfonylurea.
Sitagliptin warnings and precautions
▾
- Pancreatitis: Serious, sometimes fatal cases have been reported. Stop the medicine if it is suspected.
- Heart failure: Seen with two other DPP-4 inhibitors. Use caution if you have risk factors, such as prior heart failure or kidney problems, and report symptoms right away.
- Kidney failure: Reported after approval, sometimes needing dialysis. Kidney function should be checked.
- Serious allergic reactions: These include anaphylaxis, angioedema and Stevens-Johnson syndrome. They can occur within the first 3 months, even after the first dose.
- Severe joint pain: This can start anywhere from a day to years after starting.
- Bullous pemphigoid: This blistering skin condition has led to hospitalization.
- Low blood sugar: Risk is higher with insulin or a sulfonylurea.
Sitagliptin interactions
▾
The main interactions involve other diabetes medicines that can cause low blood sugar.
- Insulin: the combination raises the risk of low blood sugar, so the insulin dose may need to be lowered.
- Sulfonylureas (insulin secretagogues): the same risk applies, so a lower dose may be needed.
Interactions listed in the FDA-approved label
From the Sitagliptin prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Insulin secretagogues (e.g., sulfonylurea) or insulin: Coadministration of sitagliptin with an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. Lower doses of the insulin secretagogue or insulin may be required.
Read the label’s full interactions text
7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of sitagliptin with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions ( 5.4 )].
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Sitagliptin
▾
- Do not take it if you have had a serious allergic reaction to sitagliptin.
- Not for type 1 diabetes.
- Tell your doctor about any history of pancreatitis, heart failure or kidney problems.
- Use caution if you have had angioedema with another DPP-4 inhibitor.
- Pregnancy: data are limited, and poorly controlled diabetes carries risks for mother and baby.
- Breastfeeding: it is unknown whether it passes into human milk.
- Children: safety and effectiveness have not been established.
- Older adults: kidney function should be checked more often.
Sitagliptin overdose
▾
If you take too much sitagliptin, contact Poison Control. Care is supportive, which may include monitoring and an electrocardiogram (ECG). Sitagliptin is only modestly removed by hemodialysis.
What Sitagliptin does in the body
▾
Sitagliptin blocks DPP-4 activity for 24 hours. After a meal, active GLP-1 and GIP levels rise 2- to 3-fold, glucagon falls, and insulin release responds better to glucose. This lowers fasting glucose and the blood sugar rise after meals. In healthy people, it did not lower blood sugar or cause hypoglycemia.
How your body processes Sitagliptin
▾
Sitagliptin is absorbed well, reaching peak levels in 1 to 4 hours, and food does not affect it. Its half-life is about 12 hours. Most of it leaves the body unchanged in the urine, and only a small amount is metabolized. Kidney impairment raises levels in the body, which is why lower doses are used.
How to store Sitagliptin
▾
Store at 20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Sitagliptin
256 supplements and herbal products have documented interactions with Sitagliptin in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 2
- Moderate · 215
- Minor · 39
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Sitagliptin has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Sitagliptin: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Sitagliptin — the kind of thing our pharmacy team would talk through with you at the counter.
What is sitagliptin for?
▾
How do I take it?
▾
What side effects should I expect?
▾
When should I call my doctor right away?
▾
Can I take it with my other diabetes medicines?
▾
Do my kidneys matter with this medicine?
▾
Is Sitagliptin available over the counter?
▾
When was Sitagliptin first available?
▾
Who makes Sitagliptin?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Sitagliptin on HelloPharmacist
Sitagliptin forms and strengths (how it comes)
Sitagliptin is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Sitagliptin inactive ingredients by manufacturer.
Tablet
How this form is used
- Januvia, Zituvio and sitagliptin tablets are used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Januvia, Zituvio and sitagliptin tablets are taken by mouth once daily, with or without food.
- Januvia, Zituvio and sitagliptin tablets are dosed lower in people with moderate or severe kidney impairment.
- Januvia, Zituvio and sitagliptin tablets can be taken without regard to the timing of dialysis.
Oral solution
How this form is used
- Brynovin is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Brynovin is taken by mouth once daily, with or without food.
- Measure Brynovin with a calibrated oral syringe or dosing cup marked in mL.
- Brynovin dosing is lowered for people with moderate or severe kidney impairment.
Topical cream, ointment or gel
Sitagliptin on the U.S. market: products, makers and brands
How Sitagliptin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
10 companies list 36 Sitagliptin product records with the FDA, mostly as tablet, oral solution, topical cream, ointment or gel; the earliest marketing or approval year on record is 2006. Brand names on the directory include Januvia, Zituvio, Brynovin; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (50) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Sitagliptin is used (Medicaid data)
A general measure of how commonly Sitagliptin is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Sitagliptin is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Sitagliptin prescribed? Of the 1,601 medications we measure, Sitagliptin ranks #223 by Medicaid prescriptions — more than 86% of them.
Utilization by Sitagliptin product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
sitagliptin phosphate 100 MG Oral Tablet Most dispensed
Summed across the 4 of 27 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2709603
sitagliptin phosphate 50 MG Oral Tablet
Summed across the 3 of 15 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2709608
sitagliptin phosphate 25 MG Oral Tablet
Summed across the 3 of 15 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2709612
sitagliptin 100 MG Oral Tablet
Summed across the 3 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 665033
sitagliptin 50 MG Oral Tablet
Summed across the 3 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 665042
sitagliptin 25 MG Oral Tablet
Summed across the 2 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 665038
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Sitagliptin, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 18 of 86 listed Sitagliptin NDCs with Medicaid activity.
Compare Sitagliptin products
A representative set of FDA-listed product records for Sitagliptin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Oral solution | ||||
| 25 mg/mL | Oral | Azurity Pharmaceuticals, Inc. | NDA | View NDC → |
| 💊Tablet | ||||
| 25 mg | Oral | A-S Medication Solutions × 2 listings | NDA | View NDC → |
| 50 mg | Oral | A-S Medication Solutions × 2 listings | NDA | View NDC → |
| 100 mg | Oral | A-S Medication Solutions × 2 listings | NDA | View NDC → |
| 25 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 50 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 100 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 50 mg | Oral | Cardinal Health 107, LLC | NDA | View NDC → |
| 100 mg | Oral | Cardinal Health 107, LLC | NDA | View NDC → |
| 25 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 50 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 100 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 25 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 50 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 100 mg | Oral | Merck Sharp & Dohme LLC | NDA | View NDC → |
| 25 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 50 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 100 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 25 mg | Oral | Teva Pharmaceuticals, Inc. | ANDA | View NDC → |
| 50 mg | Oral | Teva Pharmaceuticals, Inc. | ANDA | View NDC → |
| 100 mg | Oral | Teva Pharmaceuticals, Inc. | ANDA | View NDC → |
| 25 mg | Oral | Zydus Lifesciences Limited | NDA AUTHORIZED GENERIC | View NDC → |
| 25 mg | Oral | Zydus Lifesciences Limited | NDA | View NDC → |
| 50 mg | Oral | Zydus Lifesciences Limited | NDA AUTHORIZED GENERIC | View NDC → |
| 50 mg | Oral | Zydus Lifesciences Limited | NDA | View NDC → |
| 100 mg | Oral | Zydus Lifesciences Limited | NDA AUTHORIZED GENERIC | View NDC → |
| 100 mg | Oral | Zydus Lifesciences Limited | NDA | View NDC → |
| 25 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 25 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | NDA | View NDC → |
| 50 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | NDA | View NDC → |
| 50 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 100 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 100 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | NDA | View NDC → |
Showing 36 of 36 products — FDA National Drug Code Directory. See every product, package size and price: browse all 36 Sitagliptin NDCs →
Sitagliptin side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Sitagliptin — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Sitagliptin are blood glucose increased, nausea, diarrhoea; about 65% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Sitagliptin in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Sitagliptin FDA approval history
How Sitagliptin went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Sitagliptin was first approved by the FDA in 2006 (Brand: JANUVIA · Msd); the first generic version was approved in 2025. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Sitagliptin recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Sitagliptin recalls since July 2021.
✅No Sitagliptin recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 593411 2 dose forms · 7 strengths
-
Dose form (SCDF) Oral Solution RxCUI 2716484In current FDA listingsClinical drug / strength (SCD) 25 MG/MLRxCUI 2716485 -
Dose form (SCDF) Oral Tablet RxCUI 665032In current FDA listingsClinical drug / strength (SCD) phosphate 100 MGRxCUI 2709603phosphate 25 MGRxCUI 2709612phosphate 50 MGRxCUI 270960825 MGRxCUI 66503850 MGRxCUI 665042100 MGRxCUI 665033
Look up RxCUI 593411 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Sitagliptin supply and shortage status
Whether Sitagliptin is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Sitagliptin costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Film Coated · Oral | 50 mg | $10.55 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 25 mg | $10.54 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 100 mg | $10.55 per tablet | NDC details & price history |
| Tablet · Oral | 100 mg | $10.08 per tablet | NDC details & price history |
| Tablet · Oral | 50 mg | $10.05 per tablet | NDC details & price history |
| Tablet · Oral | 25 mg | $10.05 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Sitagliptin brand names
Sitagliptin is sold under 3 brand names in the FDA directory — Januvia, Zituvio, Brynovin. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Sitagliptin: manufacturers and labelers
10 companies list Sitagliptin products with the FDA. By number of product records, the largest are A-S Medication Solutions, Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sitagliptin drug class (RxNorm)
Sitagliptin belongs to the Dipeptidyl Peptidase 4 Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Sitagliptin page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Cardinal Health is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →